PORTLAND, Ore., May 8, 2008 -- Znomics, Inc. , a pioneer in the development of the zebrafish as a vertebrate genetic platform to accelerate drug discovery, announced today a collaborative research program with the University of Utah and its Huntsman Cancer Institute to develop pre-clinical compounds for the treatment of T-cell leukemia, autoimmune diseases, inflammation and complications ...
AutoImmune Inc. today reported a net loss of $107,000, or per share basic and diluted, for the three months ended March 31, 2008, compared with net income of $8,000, or break even per share basic and diluted, for the three months ended March 31, 2007.
Micromet, Inc. , a biopharmaceutical company focusing on the development of novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced its financial results for the first quarter ended March 31, 2008.
Press Release May 08, 2008 KeyNeurotek Pharmaceuticals AG Reports Positive Phase I Data of Its Cannabinoid Receptor-Agonist Magdeburg, May 08, 2008 - KeyNeurotek Pharmaceuticals AG, a biotechnology company focused on the development and marketing of drugs against autoimmune diseases and degenerative disorders of the central nervous system (CNS), today announced positive results of a Phase I ...
